The U.S. Food and Drug Administration ordered a hold on a study of an early-stage obesity drug being developed by Amgen, another potential setback in the company’s efforts to join the booming weight ...

The company said the agency's hold was "not related to the drug,” dubbed AMG 513, and that discussions were underway to ...

Helicore, which is developing a GIP-blocking antibody, is the fourth obesity drug developer to receive funding from Versant in recent months.

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion. The drugmaker ...

Despite that assessment, shares in Amgen lost nearly 5% of their value ... better weight loss than Wegovy and roughly in line with Zepbound, which William Blair has now acknowledged is below ...

Shares of Viking Therapeutics and Amgen, which are currently developing ... market is operating like a duopoly between LLY and NVO, Zepbound continues to maintain the best-in-class title for ...

Given the number of comorbidities associated with obesity, the market's growth will impact the entire cardiometabolic disease ...

GLP-1 drugs Mounjaro and Zepbound drive a big revenue increase for the drugmaker Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound ...